Generic Name and Formulations:
Naltrexone HCl 50mg; scored tabs.
Indications for REVIA:
Adjunct in treatment of alcohol or narcotic dependence.
Confirm 7–10 day opioid-free period, if questionable do Narcan challenge test (see literature). ≥18yrs: Alcoholism: 50mg daily. Narcotic dependence: Initially 25mg, if no withdrawal symptoms increase to 50mg daily; alternative dosing schedules: see literature.
<18yrs: not recommended.
Concomitant opioids, current opioid dependence, or acute opioid withdrawal. Failed Narcan challenge test or (+) urine screen for opioids. Acute hepatitis. Liver failure.
Liver disease. Monitor liver function. Warn patients of danger of attempting to overcome opiate blockade. Severe renal dysfunction. Possible acute abstinence syndrome. Depression. Suicidal ideation. Pregnancy (Cat.C). Nursing mothers.
Thioridazine increases sedation. Antagonizes opioids (eg, antitussives, antidiarrheals, analgesics). Disulfiram.
Hepatotoxicity, withdrawal reactions; others, see literature.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- IL-23 Drives Castration-Resistant Prostate Cancer
- Immediate Instillation of Mitomycin C Post-TURBT May Benefit All Patients with Bladder Cancer
- Lenalidomide-Based Maintenance Therapy May Be the Most Effective in Myeloma
- Approximately Two-Thirds of Patients With Stage IV Bladder Cancer Remain Untreated
- Aspirin and Colorectal Cancer